Corvi Federico, La Spina Carlo, Benatti Lucia, Querques Lea, Lattanzio Rosangela, Bandello Francesco, Querques Giuseppe
Department of Ophthalmology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy.
Department of Ophthalmology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, University Vita-Salute San Raffaele, Milan, Italy; Department of Ophthalmology, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
Am J Ophthalmol. 2015 Jul;160(1):45-52.e1. doi: 10.1016/j.ajo.2015.04.019. Epub 2015 Apr 18.
To investigate the short-term effects of intravitreal ranibizumab on retinal vessel functionality in patients with retinal vein occlusion (RVO).
Prospective, interventional case series.
We enrolled 11 eyes of 11 consecutive treatment-naïve patients with macular edema secondary to RVO. All patients underwent a complete ophthalmic evaluation, including optical coherence tomography and dynamic and static retinal vessel analysis, using the Dynamic Vessel Analyzer (Imedos, Jena, Germany) before (baseline) and 1 week and 1 month after administration of intravitreal ranibizumab. Investigations of RVO patients were compared to 11 eyes of age- and sex-matched control subjects.
In RVO patients, dynamic analysis showed a significant increase of mean venous dilation from +2.46% ± 1.03% at baseline to +3.96% ± 1.3% at 1 week (P = .001). At 1 week mean maximum venous and arterial dilations did not differ from those of control subjects. Static analysis showed a mean overall significant decrease of central retinal artery equivalent and central retinal vein equivalent from baseline to 1 week (from 174.8 ± 22.5 measurement units [MU] to 167.2 ± 26.7 MU [P = .04], and from 228.4 ± 20.7 MU to 217.3 ± 22.8 [P = .0002]). Mean central retinal artery equivalent in healthy control subjects was 175.9 ± 10.45 MU, not significantly different from baseline, week 1, and month 1 of RVO eyes. Conversely, mean central retinal vein equivalent was 195.5 ± 9.91 MU in healthy control subjects, significantly different from baseline, week 1, and month 1 of RVO eyes.
Using the Dynamic Vessel Analyzer in patients with RVO, we found that intravitreal ranibizumab increased vein dilation (dynamic analysis) and had a vasoconstrictive effect on both arteries and veins (static analysis).
研究玻璃体内注射雷珠单抗对视网膜静脉阻塞（RVO）患者视网膜血管功能的短期影响。
前瞻性干预性病例系列研究。
我们纳入了11例连续的初治黄斑水肿继发于RVO的患者的11只眼。所有患者在玻璃体内注射雷珠单抗前（基线）、注射后1周和1个月均接受了全面的眼科评估，包括光学相干断层扫描以及使用动态血管分析仪（德国耶拿Imedos公司）进行动态和静态视网膜血管分析。将RVO患者的检查结果与年龄和性别匹配的对照受试者的11只眼进行比较。
在RVO患者中，动态分析显示平均静脉扩张从基线时的+2.46%±1.03%显著增加至1周时的+3.96%±1.3%（P = 0.001）。在1周时，平均最大静脉和动脉扩张与对照受试者无差异。静态分析显示从基线到1周，视网膜中央动脉当量和视网膜中央静脉当量总体平均显著下降（从174.8±22.5测量单位[MU]降至167.2±26.7 MU[P = 0.04]，以及从228.4±20.7 MU降至217.3±22.8[P = 0.0002]）。健康对照受试者的平均视网膜中央动脉当量为175.9±10.45 MU，与RVO眼的基线、第1周和第1个月无显著差异。相反，健康对照受试者的平均视网膜中央静脉当量为195.5±9.91 MU，与RVO眼的基线、第1周和第1个月有显著差异。
在RVO患者中使用动态血管分析仪，我们发现玻璃体内注射雷珠单抗可增加静脉扩张（动态分析），并对动脉和静脉均有血管收缩作用（静态分析）。
